SIGA Technologies, Inc. (SIGA) is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses. The Company is also engaged in the discovery and development of other anti-infectives, vaccines, and antibiotics for the prevention and treatment of serious infectious diseases. The Company’s anti-viral programs are designed to prevent or limit the replication of viral pathogens. SIGA’s anti-infectives programs target the increasingly serious problem of drug resistant bacteria and emerging pathogens.